CD45BE-HSPC cells therapy (Kite Pharma)

N/A

Report date: 2026/05/09 20:00:18

Base Information

Drug NameCD45BE-HSPC cells therapy (Kite Pharma)
Drug Alias NameCD45 base edited hematopoietic stem and progenitor cells therapy (Kite Pharma)
ClassificationCell and gene therapy > Cell therapy > Stem cell therapy > Hematopoietic stem cells therapy
Mechanisms of ActionAnti-CD45Stem cell replacements
TargetsLeukocyte common antigen
Therapy Area/IndicationsRichter's SyndromeLymphoma, T-CellLymphoma, B-Cell +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesKite Pharma
China Registration ClassN/A

Develop Information

Active CompaniesKite Pharma
Inactive CompaniesN/A
Active IndicationsRichter's SyndromeLymphoma, T-CellLymphoma, B-Cell +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A